Enzo Biochem (ENZ) AI Stock Analysis

• Market Cap: $22.60M
• Dividend Yield: N/A
• Average Volume (3M): 106.53K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.62
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 125
• Sector: Healthcare
• Sector Strength: 72
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.41
• Shares Outstanding: 52,402,805
• 10 Day Avg. Volume: 108,071
• 30 Day Avg. Volume: 106,525
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.88
• Price to Cash Flow (P/CF): -3.10
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Enzo Biochem's stock exhibits significant financial and operational risks, including declining revenues, negative profit margins, and NYSE compliance challenges. Technical indicators are weak, and valuation is unfavorable. The company's ability to address these issues remains a key concern.

Enzo Biochem Business Overview & Revenue Model

Company Description

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.

How the Company Makes Money

Enzo Biochem generates revenue primarily through its two operational segments. The Enzo Clinical Labs segment earns income by providing diagnostic testing services to physicians, medical centers, and other healthcare facilities. This segment is a key revenue driver due to the high volume of tests it conducts, which includes both routine and specialized testing services. The Enzo Life Sciences segment, on the other hand, generates revenue through the sale of life science research products and tools that include antibodies, proteins, assays, and small molecules. This segment caters to a global market of academic and government institutions, biotechnology and pharmaceutical companies. Enzo Biochem's revenue model is supported by its proprietary technologies and strategic partnerships, which enhance its capabilities in product development and distribution.

Enzo Biochem Financial Statement Overview

Summary

Enzo Biochem faces considerable financial challenges, with declining revenues, negative profit margins, and cash flow difficulties. The balance sheet shows low leverage and substantial equity, but persistent losses and cash flow issues present significant risks.

Income Statement

Enzo Biochem's income statement shows significant challenges with profitability. The TTM (Trailing-Twelve-Months) data indicates a negative gross profit margin of 45.6%, a net profit margin of -73.2%, and declining revenue trends. The company has struggled to maintain positive EBIT and EBITDA margins, reflecting operational inefficiencies and high costs relative to revenue.

Balance Sheet

The balance sheet reveals moderate financial stability. Enzo Biochem has a low debt-to-equity ratio of 0.06, indicating low financial leverage. The equity ratio stands at 69%, which is a positive sign of financial health. However, the return on equity (ROE) is negative due to ongoing losses, which could deter potential investors.

Cash Flow

The cash flow statement highlights cash flow issues, with negative operating and free cash flows in the TTM (Trailing-Twelve-Months). The company struggles with cash generation, as evidenced by the negative free cash flow to net income ratio. However, cash reserves remain substantial, which could help mitigate short-term liquidity risks.

Breakdown
TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement		Total Revenue
29.09M	31.91M	31.06M	107.07M	117.73M	76.02M
	Gross Profit
13.27M	14.63M	11.57M	41.97M	53.58M	23.77M
	EBIT
-8.69M	-9.82M	-24.74M	-15.51M	9.88M	-23.64M
	EBITDA
-7.36M	-8.35M	-20.94M	-15.01M	3.35M	-27.59M
	Net Income Common Stockholders
-21.31M	-26.08M	20.29M	-22.58M	3.42M	-33.89M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
31.56M	52.37M	82.37M	21.60M	43.50M	47.87M
	Total Assets
115.45M	85.76M	121.88M	95.86M	113.69M	112.54M
	Total Debt
0.00	3.51M	7.00M	20.59M	22.68M	32.79M
	Net Debt
-8.75M	-48.86M	-75.38M	-1.02M	9.15M	-15.07M
	Total Liabilities
18.52M	29.65M	43.42M	41.40M	45.10M	54.16M
	Stockholders Equity
96.92M	56.11M	78.46M	54.46M	68.59M	58.38M
Cash Flow		Free Cash Flow
-15.75M	-26.80M	-39.74M	-20.06M	-4.05M	-19.35M
	Operating Cash Flow
-14.96M	-26.26M	-36.98M	-16.59M	387.00K	-17.18M
	Investing Cash Flow
4.22M	-545.00K	98.98M	25.22M	-34.50M	-2.17M
	Financing Cash Flow
-9.18M	-4.19M	-1.13M	-241.00K	-242.00K	7.00M

Enzo Biochem Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.37
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENZ, the sentiment is Negative. The current price of 0.37 is below the 20-day moving average (MA) of 0.46, below the 50-day MA of 0.52, and below the 200-day MA of 0.87, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 24.56 is Positive, neither overbought nor oversold. The STOCH value of 17.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENZ.

Enzo Biochem Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	49 Neutral	$6.85B	0.81	-52.91%	2.50%	17.48%	1.17%
ENZ	45 Neutral	$22.60M	―	-12.94%	―	―	―
IGC	45 Neutral	$23.43M	―	-115.06%	―	1.64%	50.63%
CARA	44 Neutral	$23.55M	―	-270.01%	―	-65.96%	40.80%
ENLV	36 Underperform	$22.43M	―	-57.93%	―	―	32.42%
BCAB	31 Underperform	$21.66M	―	-164.30%	―	―	44.38%
NRSN	28 Underperform	$23.11M	―	539.33%	―	―	24.35%

Enzo Biochem Corporate Events

Enzo Biochem Faces NYSE Compliance Challenges

On January 8, 2025, Enzo Biochem, Inc. received a notice of non-compliance from the New York Stock Exchange, as its market capitalization and stockholder’s equity fell below $50 million, and its average stock price was under $1.00 for 30 consecutive trading days. The company has 18 months to address the capitalization and equity issues and six months to resolve the stock price deficiency, during which its stock will continue trading on the NYSE. Enzo Biochem plans to submit a corrective plan by February 21, 2025, and is considering various alternatives to regain compliance, ensuring its continued listing on the exchange while maintaining adherence to other NYSE standards.